Hepion Pharma Executives Bulk Buy Shares at Half‑Price, Signaling Bold Bet on Liver‑Disease Breakthroughs
Insider buying surge at Hepion Pharmaceuticals signals confidence in NASH and HBV therapy prospects, despite high volatility and clinical‑stage risk.
2 minutes to read